AbbVie, Thermo Fisher Scientific, Danaher, GSK, Vertex Pharmaceuticals, Polyrizon, and Moderna are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies whose core business is researching, developing and commercializing products—such as drugs, diagnostics or gene therapies—using biological processes. Their prices tend to be volatile because they’re heavily influenced by clinical trial outcomes, regulatory approvals and scientific breakthroughs. Investors in biotech stocks often balance the sector’s high growth potential against considerable risks and long development timelines. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
NYSE ABBV traded down $3.82 during mid-day trading on Tuesday, reaching $186.06. 1,906,256 shares of the stock were exchanged, compared to its average volume of 6,285,921. AbbVie has a one year low of $163.81 and a one year high of $218.66. The stock has a 50 day simple moving average of $186.92 and a 200-day simple moving average of $189.21. The stock has a market cap of $328.66 billion, a P/E ratio of 79.16, a P/E/G ratio of 1.28 and a beta of 0.48. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.76 and a quick ratio of 0.64.
Read Our Latest Research Report on ABBV
Thermo Fisher Scientific (TMO)
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
NYSE TMO traded down $2.07 during mid-day trading on Tuesday, reaching $423.28. 591,736 shares of the stock were exchanged, compared to its average volume of 1,997,821. Thermo Fisher Scientific has a one year low of $385.46 and a one year high of $627.88. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.77 and a quick ratio of 1.38. The stock has a market cap of $159.78 billion, a P/E ratio of 24.79, a P/E/G ratio of 2.31 and a beta of 0.77. The stock has a 50 day simple moving average of $409.45 and a 200-day simple moving average of $475.17.
Read Our Latest Research Report on TMO
Danaher (DHR)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
DHR traded down $1.50 during midday trading on Tuesday, hitting $196.26. The company had a trading volume of 1,179,835 shares, compared to its average volume of 3,505,223. Danaher has a 52 week low of $171.00 and a 52 week high of $281.70. The company has a quick ratio of 1.05, a current ratio of 1.43 and a debt-to-equity ratio of 0.31. The company has a market capitalization of $140.45 billion, a price-to-earnings ratio of 38.07, a PEG ratio of 2.88 and a beta of 0.77. The stock's 50 day moving average price is $196.06 and its 200 day moving average price is $205.89.
Read Our Latest Research Report on DHR
GSK (GSK)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
GSK traded down $0.44 during midday trading on Tuesday, hitting $37.85. The company had a trading volume of 5,281,882 shares, compared to its average volume of 4,993,292. The company has a market capitalization of $77.50 billion, a price-to-earnings ratio of 19.49, a PEG ratio of 1.54 and a beta of 0.50. The stock's 50 day moving average price is $38.97 and its 200 day moving average price is $37.33. GSK has a 52 week low of $31.72 and a 52 week high of $44.67. The company has a quick ratio of 0.58, a current ratio of 0.87 and a debt-to-equity ratio of 1.21.
Read Our Latest Research Report on GSK
Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Shares of NASDAQ VRTX traded down $6.10 during midday trading on Tuesday, reaching $466.25. The company's stock had a trading volume of 245,767 shares, compared to its average volume of 1,419,375. Vertex Pharmaceuticals has a 12-month low of $377.85 and a 12-month high of $519.88. The firm has a 50 day moving average price of $447.15 and a 200-day moving average price of $461.56. The stock has a market capitalization of $119.73 billion, a P/E ratio of -118.88 and a beta of 0.41. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.65 and a quick ratio of 2.29.
Read Our Latest Research Report on VRTX
Polyrizon (PLRZ)
Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.
Shares of NASDAQ:PLRZ traded up $0.37 during mid-day trading on Tuesday, reaching $1.05. The company had a trading volume of 99,845,549 shares, compared to its average volume of 2,054,307. The company's 50-day moving average price is $14.58 and its 200-day moving average price is $153.27. Polyrizon has a one year low of $0.55 and a one year high of $1,200.00.
Read Our Latest Research Report on PLRZ
Moderna (MRNA)
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Shares of NASDAQ:MRNA traded down $0.81 during mid-day trading on Tuesday, reaching $32.06. The company had a trading volume of 3,199,950 shares, compared to its average volume of 8,847,263. The firm has a market cap of $12.40 billion, a price-to-earnings ratio of -3.66 and a beta of 1.84. The company's 50-day moving average price is $27.21 and its 200-day moving average price is $31.09. Moderna has a one year low of $23.15 and a one year high of $127.20.
Read Our Latest Research Report on MRNA
Read More
Before you consider AbbVie, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.
While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
